Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 December;60(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 December;60(4):354-61

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

REVIEWS  AN UPDATE ON NUCLEAR CARDIOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 December;60(4):354-61

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy

Roberto SCIAGRÀ

Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy


PDF


In the setting of hypertrophic cardiomyopathy (HCM), ischemia plays a possibly under-evaluated role. In particular, a large body of evidence indicates that structural and functional abnormalities in the coronary microcirculation contribute to myocardial ischemia and are key elements for HCM pathophysiology and clinical evolution. Measurement of myocardial blood flow (MBF) at rest and under maximal hyperemia (hMBF) by means of perfusion positron-emission tomography (PET) is the most effective way to assess microvascular dysfunction in humans. Therefore, hMBF abnormalities reflect HCM severity and correlate with other important features, such as ischemic symptoms and myocardial fibrosis. Most importantly, it has been demonstrated that severely blunted hMBF implies an adverse outcome in HCM patients. Therefore, PET could be helpful for stratifying patient prognosis and should be used in selected patient subsets to identify those at risk of unfavorable evolution.

top of page